HK1205515A1 - Guanine analogs as telomerase substrates and telomere length affectors - Google Patents

Guanine analogs as telomerase substrates and telomere length affectors

Info

Publication number
HK1205515A1
HK1205515A1 HK15103664.2A HK15103664A HK1205515A1 HK 1205515 A1 HK1205515 A1 HK 1205515A1 HK 15103664 A HK15103664 A HK 15103664A HK 1205515 A1 HK1205515 A1 HK 1205515A1
Authority
HK
Hong Kong
Prior art keywords
affectors
telomere length
guanine analogs
telomerase substrates
telomerase
Prior art date
Application number
HK15103664.2A
Other languages
English (en)
Chinese (zh)
Inventor
Sergei M Gryaznov
Ronald A Pruzan
Krisztina Pongracz
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of HK1205515A1 publication Critical patent/HK1205515A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15103664.2A 2011-12-22 2015-04-15 Guanine analogs as telomerase substrates and telomere length affectors HK1205515A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161579575P 2011-12-22 2011-12-22
PCT/US2012/000586 WO2013095684A1 (en) 2011-12-22 2012-12-21 Guanine analogs as telomerase substrates and telomere length affectors

Publications (1)

Publication Number Publication Date
HK1205515A1 true HK1205515A1 (en) 2015-12-18

Family

ID=48669322

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103664.2A HK1205515A1 (en) 2011-12-22 2015-04-15 Guanine analogs as telomerase substrates and telomere length affectors

Country Status (8)

Country Link
US (5) US9593137B2 (xx)
EP (2) EP3578563B1 (xx)
JP (2) JP6113185B2 (xx)
CA (1) CA2857490C (xx)
DK (2) DK3578563T3 (xx)
ES (2) ES2874774T3 (xx)
HK (1) HK1205515A1 (xx)
WO (1) WO2013095684A1 (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
US9822138B2 (en) 2015-08-10 2017-11-21 Merck Sharp & Dohme Corp. Antiviral beta-amino acid ester phosphodiamide compounds
EP3386512B1 (en) 2015-12-10 2023-11-22 Merck Sharp & Dohme LLC Antiviral phosphodiamide prodrugs of tenofovir
WO2017106069A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
EP3532069A4 (en) 2016-10-26 2020-05-13 Merck Sharp & Dohme Corp. ARYL-AMIDE PHOSPHODIAMIDE COMPOUNDS ANTIVIRALS
EP3558322B1 (en) 2016-12-22 2021-09-29 Merck Sharp & Dohme Corp. Antiviral benzyl-amine phosphodiamide compounds
TWI784370B (zh) * 2017-01-31 2022-11-21 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
EP3823629A4 (en) 2018-07-19 2022-05-04 Merck Sharp & Dohme Corp. PHOSPHINAMIDE PRODRUGS OF TENOFOVIR
CN111205326B (zh) * 2020-02-13 2020-09-22 南京道尔医药科技有限公司 一种绿色环保的泰诺福韦制备方法

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5650510A (en) 1986-11-18 1997-07-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
NZ222553A (en) 1986-11-18 1991-07-26 Bristol Myers Co Phosphonomethoxyalkylene purine and pyrimidine derivatives and pharmaceutical compositions
AU8092587A (en) 1986-11-18 1988-05-19 Bristol-Myers Squibb Company Synthesis of purin-9-ylalkylenoxymethyl phosphonic acids
EP0405748A1 (en) 1989-05-30 1991-01-02 Beecham Group p.l.c. Phosphonoderivative of purine with antiviral activity
ATE124050T1 (de) 1990-04-20 1995-07-15 Acad Of Science Czech Republic Chirale 2-(phosphonomethoxy)propyl-guanine als antivirale agentien.
CZ285420B6 (cs) 1990-04-24 1999-08-11 Ústav Organické Chemie A Biochemie Avčr N-(3-Fluor-2-fosfonylmethoxypropyl)deriváty purinových a pyrimidinových heterocyklických bazí, způsoby jejich přípravy a použití
ES2083580T3 (es) 1990-06-13 1996-04-16 Arnold Glazier Profarmacos de fosforo.
CS387190A3 (en) 1990-08-06 1992-03-18 Ustav Organicke Chemie A Bioch (2r)-2-/di(2-propyl)phosphonylmethoxy/-3-p-toluenesulfonyloxy -1- trimethylacetoxypropane and process for preparing thereof
CA2088363C (en) 1990-08-10 2002-05-28 Purushotham Vemishetti Process for the preparation of nucleotides
DK0481214T3 (da) 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
GB9020932D0 (en) 1990-09-26 1990-11-07 Wellcome Found Heterocyclic compounds
GB9026164D0 (en) 1990-12-01 1991-01-16 Beecham Group Plc Pharmaceuticals
CZ284678B6 (cs) 1991-05-20 1999-01-13 Ústav Organické Chemie A Biochemie Avčr Di(2-propyl)estery 1-fluor-2-fosfonomethoxy-3-p -toluensulfonyloxypropanů, způsob jejich přípravy a použití
EP0531597A1 (en) 1991-09-12 1993-03-17 Merrell Dow Pharmaceuticals Inc. Novel unsaturated acyclic phosphonate derivatives of purine and pyrimidine
JP3497505B2 (ja) 1991-10-11 2004-02-16 インスティテュート オブ オルガニック ケミストリー アンド バイオケミストリー オブ ザ アカデミー オブ サイエンシズ オブ ザ チェコ パブリック 抗ウイルス性非環式ホスホノメトキシアルキル置換アルケニル及びアルキニルプリン及びピリミジン誘導体
GB9205917D0 (en) 1992-03-18 1992-04-29 Smithkline Beecham Plc Pharmaceuticals
US5837453A (en) 1992-05-13 1998-11-17 Geron Corporation Telomerase activity assays
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
FR2692265B1 (fr) 1992-05-25 1996-11-08 Centre Nat Rech Scient Composes biologiquement actifs de type phosphotriesters.
US5532225A (en) 1992-07-31 1996-07-02 Sri International Acyclic purine phosphonate nucleotide analogs as antiviral agents, and related synthetic methods
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
EP0618214A1 (en) 1993-04-01 1994-10-05 Merrell Dow Pharmaceuticals Inc. Unsaturated phosphonate derivatives of purines and pyrimidines
US5817647A (en) 1993-04-01 1998-10-06 Merrell Pharmaceuticals Inc. Unsaturated acetylene phosphonate derivatives of purines
EP0632048B1 (en) 1993-06-29 2001-03-21 Mitsubishi Chemical Corporation Phosphonate-nucleotide ester derivatives
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
JP4086314B2 (ja) 1993-09-17 2008-05-14 ギリアード サイエンシーズ， インコーポレイテッド ヌクレオチドアナログ
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
EP0754046A1 (en) 1994-04-04 1997-01-22 FREEMAN, William R. Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
IT1270008B (it) 1994-09-23 1997-04-16 Ist Superiore Sanita Derivati purinici ed 8-azapurinici atti al trattamento terapeutico dell'aids
JP3906488B2 (ja) 1995-02-21 2007-04-18 味の素株式会社 プリン誘導体の製造方法
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
CN1078593C (zh) 1995-06-15 2002-01-30 三菱化学株式会社 核苷酸磷酸酯衍生物
TW369536B (en) 1996-01-18 1999-09-11 Mitsubishi Chem Corp Phosphonate nucleotide compounds
US5874577A (en) 1996-04-03 1999-02-23 Medichem Research, Inc. Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US6194398B1 (en) 1996-08-13 2001-02-27 Mitsubishi Chemical Corporation Phosphonate nucleotide compound
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
US6252061B1 (en) 1998-03-23 2001-06-26 Reliable Biopharmaceutical, Inc. Process for the production of 2-halo-6-aminopurine derivatives
SI20022A (sl) 1998-07-29 2000-02-29 Kemijski inštitut Alkilno substituirani purinovi derivati in njihova priprava
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6995145B1 (en) 1999-06-04 2006-02-07 Au Jessie L-S Methods and compositions for modulating drug activity through telomere damage
KR20070112295A (ko) 1999-09-10 2007-11-22 제론 코포레이션 올리고뉴클레오티드 엔3'→피5' 티오포스포라미데이트,이의 합성 및 용도
ATE269081T1 (de) 1999-09-24 2004-07-15 Shire Biochem Inc Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen
CA2747954C (en) 1999-12-03 2014-02-25 The Regents Of The University Of California Phosphonate compounds
WO2001044258A1 (en) 1999-12-17 2001-06-21 Ariad Pharmaceuticals, Inc. Novel heterocycles
US20030187261A1 (en) 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
KR20020093824A (ko) 2000-02-29 2002-12-16 미쯔비시 웰 파마 가부시키가이샤 포스포네이트 뉴클레오티드 화합물
KR100749160B1 (ko) 2000-07-21 2007-08-14 길리애드 사이언시즈, 인코포레이티드 포스포네이트 뉴클레오티드 유사체의 전구 약물의 제조방법
WO2002069949A2 (en) * 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
KR20020097384A (ko) 2001-06-20 2002-12-31 미쯔비시 도꾜 세이야꾸 가부시끼가이샤 기존의 약제에 내성변이를 가지는 바이러스에 유효한 약제
JP2005508924A (ja) 2001-08-30 2005-04-07 三菱ウェルファーマ株式会社 抗ウイルス剤
EA200400690A1 (ru) 2001-11-14 2005-06-30 Байокрист Фармасьютикалз, Инк. Нуклеозиды, их препараты и их применение в качестве ингибиторов вирусных рнк-полимераз
US6858393B1 (en) 2002-03-13 2005-02-22 Stratagene California Chain terminators for DNA synthesis
WO2003087302A2 (en) 2002-04-12 2003-10-23 Stratagene Dual-labeled nucleotides
WO2004037161A2 (en) 2002-05-13 2004-05-06 Metabasis Therapeutics, Inc. Cyclic prodrugs of pmea one of its analogues
AU2003242428A1 (en) 2002-05-24 2003-12-12 Mitsubishi Pharma Corporation Drugs improved in tissue selectivity
AU2003290816A1 (en) 2002-11-12 2004-06-03 Pharmasset, Inc. Modified nucleosides as antiviral agents
US20040224916A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
WO2004106350A1 (en) 2003-05-14 2004-12-09 Biocryst Pharmaceutical, Inc. Nucleoside analogs as viral polymerase inhibitors
KR101102815B1 (ko) 2003-06-16 2012-01-05 케이.유.루벤 리서치 앤드 디벨럽먼트 항바이러스 뉴클레오티드 유사체인 포스포네이트기를 갖는 피리미딘 화합물
CA2533966A1 (en) 2003-07-30 2005-02-10 Gilead Sciences, Inc. Nucleobase phosphonate analogs for antiviral treatment
ATE433974T1 (de) 2003-09-19 2009-07-15 Gilead Sciences Inc Azachinolinolphosphonatverbindungen als integraseinhibitoren
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
RS52433B (en) 2003-12-30 2013-02-28 Gilead Sciences Inc. NUCLEOSIDE PHOSPHONATES AND THEIR ANALYSIS FOR THE TREATMENT OF HPV INFECTIONS
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US8063209B2 (en) 2004-07-02 2011-11-22 Tsrl, Inc. Phosphonyl ester conjugates as prodrugs
UA93354C2 (ru) 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
ITFI20040173A1 (it) 2004-08-03 2004-11-03 Protera S R L Profarmaci attivati da dna polimerasi dipendenti da rna
ES2401285T3 (es) * 2004-12-16 2013-04-18 The Regents Of The University Of California Fármacos con el pulmón como diana
CA2602562C (en) 2005-03-25 2015-07-07 Alt Solutions, Inc. Modulation of telomere length in telomerase positive cells and cancer therapy
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
ES2261072B1 (es) 2005-04-06 2007-12-16 Consejo Superior Investig. Cientificas Fosforotioatos derivados de analogos a nucleosido para terapia antirretroviral.
CA2606399A1 (en) 2005-04-25 2006-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Scienc Es Of The Czech Republic Use of compounds to enhance processivity of telomerase
WO2006125166A2 (en) 2005-05-18 2006-11-23 Alt Solutions, Inc. Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer
WO2007002912A2 (en) 2005-06-29 2007-01-04 Gilead Sciences, Inc. Anti-proliferative compounds, compositions, and methods of use thereof
WO2007014491A1 (fr) 2005-08-03 2007-02-08 Beijing Fu Kang Ren Bio-Pharm Tech.Co.Ltd. Phosphonates de nucléotides acycliques et leur utilisation dans des agents antiviraux
WO2007106450A2 (en) 2006-03-10 2007-09-20 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy
EP2012799B1 (en) 2006-05-03 2016-08-24 Chimerix, Inc. Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
WO2008001953A1 (en) 2006-06-30 2008-01-03 Panasonic Corporation Node discovery method for providing optimal path preserving location privacy
WO2008005555A1 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc. Modulators of toll-like receptor 7
FR2908133B1 (fr) 2006-11-08 2012-12-14 Centre Nat Rech Scient Nouveaux analogues de nucleotides comme molecules precurseurs d'antiviraux
JP2010525063A (ja) 2007-04-27 2010-07-22 キメリクス，インコーポレイテッド ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法
WO2008134578A2 (en) 2007-04-28 2008-11-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Synthesis of optically active radio-labeled reverse transcriptase inhibitors
GB0709408D0 (en) 2007-05-16 2007-06-27 Katholleke Universiteit Leuven Anti-col herpes virus compounds
CN105055432A (zh) 2008-01-25 2015-11-18 奇默里克斯公司 治疗病毒感染的方法
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
WO2009115927A2 (en) 2008-03-18 2009-09-24 Institut De Recherches Cliniques De Montreal Nucleotide analogues with quaternary carbon stereogenic centers and methods of use
US20100081713A1 (en) 2008-03-19 2010-04-01 CombinatoRx, (Singapore) Pte. Ltd. Compositions and methods for treating viral infections
US20110059921A1 (en) 2008-03-27 2011-03-10 Ektar Therapeutics Oligomer-Nitrogenous Base Conjugates
WO2009129094A2 (en) 2008-04-15 2009-10-22 Mallinckrodt Inc. Compositions containing antiviral compounds and methods of using the same
EP2320991B1 (en) 2008-08-21 2020-05-20 Kibur Medical, Inc. Device for drug evaluation and local treatment
KR101774429B1 (ko) 2009-02-06 2017-09-04 코크리스탈 파마, 아이엔씨. 암 및 바이러스 감염 치료용 퓨린 뉴클레오시드 모노포스페이트 프로드럭
WO2011011710A1 (en) 2009-07-24 2011-01-27 Chimerix, Inc. Methods of treating viral infections
WO2011017253A1 (en) 2009-08-03 2011-02-10 Chimerix, Inc. Composition and methods of treating viral infections and viral induced tumors
EP2493479A4 (en) 2009-10-30 2013-04-17 Chimerix Inc METHOD FOR THE TREATMENT OF VIRUS DISEASES
MX2012006485A (es) 2009-12-07 2012-08-23 Univ Georgia Piridinon hidroxiclicopentil carboxamidas: inhibidores de la integrasa del vih con aplicaciones terapeuticas.
CN102093422B (zh) 2009-12-10 2015-02-25 中国人民解放军军事医学科学院毒物药物研究所 无环核苷膦酸酯衍生物及其医药用途
US20130028920A1 (en) 2010-03-31 2013-01-31 Universite De Geneve Stabilized antibody preparations and uses thereof
EP2558466A4 (en) 2010-04-14 2013-11-13 Univ California PHOSPHONATES HAVING REDUCED TOXICITY FOR THE TREATMENT OF VIRAL INFECTIONS
WO2011133963A2 (en) 2010-04-23 2011-10-27 University Of Southern California Tyrosine-based prodrugs of antiviral agents
EP2582712A4 (en) 2010-06-18 2013-12-04 Us Health USEFUL LIQUID PURINE-PTERINATED HPPK INHIBITORS AS ANTIBACTERIAL AGENTS
CZ201126A3 (cs) * 2011-01-18 2012-05-09 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Zpusob výroby substituovaných diamidu fosfonových kyselin

Also Published As

Publication number Publication date
EP2794624B1 (en) 2019-05-15
DK2794624T3 (da) 2019-07-22
US20150299232A1 (en) 2015-10-22
US20200283461A1 (en) 2020-09-10
ES2734495T3 (es) 2019-12-10
US20220306660A1 (en) 2022-09-29
EP2794624A1 (en) 2014-10-29
EP2794624A4 (en) 2015-04-29
US11279720B2 (en) 2022-03-22
US20170233419A1 (en) 2017-08-17
US9593137B2 (en) 2017-03-14
CA2857490C (en) 2020-03-31
WO2013095684A1 (en) 2013-06-27
CA2857490A1 (en) 2013-06-27
JP2015502979A (ja) 2015-01-29
JP6113185B2 (ja) 2017-04-12
ES2874774T3 (es) 2021-11-05
DK3578563T3 (da) 2021-05-31
US10562926B2 (en) 2020-02-18
EP3578563A1 (en) 2019-12-11
US20190106447A1 (en) 2019-04-11
EP3578563B1 (en) 2021-04-14
US10035814B2 (en) 2018-07-31
JP2017081961A (ja) 2017-05-18

Similar Documents

Publication Publication Date Title
HK1205515A1 (en) Guanine analogs as telomerase substrates and telomere length affectors
HK1216254A1 (zh) 取代的核苷酸類似物
HK1203513A1 (en) Methods of preparing substituted nucleotide analogs
SG11201404918YA (en) Etching composition
EP2826473A4 (en) NEW USE OF PATCHOULOL
EP2921510A4 (en) SURFACE TREATMENT COMPOSITION
HK1208173A1 (en) Bromocriptine formulations
GB201118636D0 (en) Nucleotide sequence
HK1176414A1 (en) Decorated enamelled part
HK1207384A1 (en) Process for the preparation of 2-deoxy-2-fluoro-2-methyl-d- ribofuranosyl nucleoside compounds 2--2--2--d-
EP2917314A4 (en) OLIGOMERATZUSAMMENSETZUNG
GB2479833B (en) Modified nucleotides
EP2754451A4 (en) USE OF ACHE AS NUCLEASE
EP2812190A4 (en) SURFACE TREATMENT COMPOSITION
GB2512737B (en) Micro-Fermentation of cocoa
ZA201406203B (en) Adjuvant compositions
EP2861738A4 (en) METHODS AND COMPOSITIONS ASSOCIATED WITH THE SMCHD1 GENE
EP2824698A4 (en) SUSCEPTOR
EP2691106A4 (en) ANTIVIRAL COMPOSITION
EP2803080A4 (en) susceptor
TWM433124U (en) Structure of decoration article
EP2782585A4 (en) ANTIVIRAL PREPARATIONS
ZA201306909B (en) Antiviral composition
EP2802655A4 (en) NUCLEOTIDE CLONING METHODS
PL2856498T3 (pl) Susceptor